Alyeska Investment Group L.P. Trims Stake in Moderna, Inc. $MRNA

Alyeska Investment Group L.P. cut its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 86.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 560,819 shares of the company's stock after selling 3,490,366 shares during the period. Alyeska Investment Group L.P. owned about 0.14% of Moderna worth $39,274,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. BlackRock Inc. bought a new stake in Moderna during the 2nd quarter worth approximately $2,142,877,000. Capital World Investors purchased a new position in shares of Moderna during the 4th quarter valued at $378,299,000. Invesco Ltd. boosted its holdings in Moderna by 15.7% in the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company's stock worth $212,223,000 after buying an additional 1,115,131 shares during the period. Theleme Partners LLP bought a new position in Moderna in the 2nd quarter worth $564,272,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Moderna by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company's stock worth $136,290,000 after buying an additional 309,126 shares in the last quarter. Institutional investors own 75.33% of the company's stock.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $137.99 on Monday. The company has a market cap of $55.09 billion, a price-to-earnings ratio of -17.27 and a beta of 0.91. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $77.11 and a 200 day moving average price of $59.85.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. The company had revenue of $145.00 million for the quarter, compared to analysts' expectations of $102.93 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The firm's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.13) earnings per share. As a group, equities research analysts predict that Moderna, Inc. will post -6.11 earnings per share for the current year.

Insider Buying and Selling at Moderna

In related news, President Stephen Hoge sold 53,336 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider directly owned 67,468 shares of the company's stock, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several research analyst reports. Morgan Stanley boosted their price objective on Moderna from $39.00 to $89.00 and gave the company an "equal weight" rating in a research report on Thursday, August 20th. Jefferies Financial Group reissued a "hold" rating on shares of Moderna in a research note on Wednesday, August 19th. Piper Sandler reissued an "overweight" rating on shares of Moderna in a report on Monday, August 3rd. Argus raised Moderna from a "hold" rating to a "buy" rating and set a $180.00 price target on the stock in a report on Friday. Finally, Loop Capital set a $135.00 price objective on shares of Moderna in a report on Wednesday, August 19th. Seven research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, Moderna has an average rating of "Hold" and an average target price of $80.53.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported that their personalized mRNA melanoma vaccine, intismeran, combined with Keytruda, met the goals of a Phase 3 study involving 1,137 patients. The treatment reduced the risk of melanoma recurrence and distant spread versus Keytruda alone, strengthening the case for Moderna’s oncology pipeline and the commercial potential of the partnership. Reuters cancer vaccine breakthrough article
• Positive Sentiment: The U.S. FDA approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID-19 vaccines, targeting the XFG subvariant. The approval preserves access to the seasonal COVID-19 vaccine market, though future demand remains an important uncertainty. Reuters FDA approval article
• Positive Sentiment: Argus upgraded Moderna from “Hold” to “Buy” and assigned a $180 price target, indicating additional potential upside based on the company’s oncology opportunity and recent clinical progress. Argus upgrade article
• Neutral Sentiment: Jim Cramer advised a viewer to hold Moderna after the stock’s sharp rally, reflecting continued optimism about the Phase 3 cancer-vaccine result but also caution following the run-up. Jim Cramer Moderna commentary
• Negative Sentiment: Moderna priced an upsized $2.6 billion offering of zero-coupon convertible senior notes due 2032, increased from the initially proposed $2.0 billion. Proceeds may fund oncology investments and debt repayment, but the larger financing raised concerns about future share dilution and explains much of the selling pressure. Moderna convertible notes offering
• Negative Sentiment: BioNTech’s decision to halt a mid-stage personalized mRNA colorectal-cancer vaccine trial after a review weakened sentiment across the mRNA oncology sector, raising broader questions about the difficulty of translating promising technology into successful cancer treatments. BioNTech colorectal cancer trial article

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source